ACADIA’s history is rooted in science and strong leadership in central nervous system (CNS) research. Since the beginning, we have been dedicated to improving the lives of patients suffering from CNS disorders. All programs in our pipeline emanate from discoveries made at ACADIA.

We invite you to learn more about our history by clicking on the year.

2016

FDA approves NUPLAZID® (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis.

FDA approves NUPLAZID® (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis.

ACADIA is added to Large-Cap Russell 1000 Index.

2015

NUPLAZID New Drug Application for Parkinson’s disease psychosis is submitted to FDA and granted Priority Review.

NUPLAZID New Drug Application for Parkinson’s disease psychosis is submitted to FDA and granted Priority Review.

Steve Davis is appointed President and Chief Executive Officer.

2014

FDA grants Breakthrough Therapy designation for NUPLAZID.

ACADIA announces trade name NUPLAZID for pimavanserin.

FDA grants Breakthrough Therapy designation to NUPLAZID (pimavanserin) for Parkinson’s disease psychosis.

2013

Data from -020 Study presented at AAN. The Lancet publishes -020 Study results.

Data from the -020 Study with pimavanserin for Parkinson’s disease psychosis is presented at the American Academy of Neurology Annual Meeting.

After meeting with the FDA, ACADIA announces an expedited path to a New Drug Application filing with pimavanserin for the treatment of Parkinson’s disease psychosis.

ACADIA is added to the NASDAQ Biotechnology and the Russell 2000 indices.

The Lancet publishes data from the Phase III -020 Study with pimavanserin for Parkinson’s disease psychosis.

2012

Positive Phase III data for pimavanserin in -020 Study is reported in patients with PDP.

Positive Phase III data for pimavanserin is reported for patients with Parkinson’s disease psychosis from the -020 Study.

2010

Phase III -020 study is initiated in PDP. ACADIA regains worldwide rights to pimavanserin.

ACADIA initiates a pivotal Phase III efficacy, tolerability and safety study with pimavanserin in patients with Parkinson’s disease psychosis (-020 Study).

Valeant purchases Biovail in 2010 and shifts the strategic focus to marketed drugs, allowing ACADIA to regain full worldwide rights to pimavanserin following the conclusion of its collaboration with Biovail.

2009

Collaboration with Biovail formed.

A collaboration with Biovail is formed to develop and commercialize pimavanserin in North America.

2007

Positive Phase II data for pimavanserin is reported as a co-therapy for patients with schizophrenia.

Positive Phase II data for pimavanserin is reported as a co-therapy for patients with schizophrenia.

2006

Positive Phase II data for pimavanserin is reported in patients with PDP.

Positive Phase II data for pimavanserin is reported in patients with Parkinson’s disease psychosis.

2004

ACADIA completes its IPO.

ACADIA completes its initial public offering and trades under the symbol “ACAD” on the NASDAQ Stock Market.

2001

Pimavanserin first synthesized by an ACADIA chemist.

Pimavanserin is synthesized by an ACADIA chemist working in the Copenhagen facility.

1999

ACADIA scientists start a project aimed at discovering 5-HT2A inverse agonists.

ACADIA scientists start a project aimed at discovering new non-dopaminergic antipsychotic agents selectively acting as inverse agonists on the 5-HT2A receptor.

1997

Company changes its name to ACADIA Pharmaceuticals Inc. and moves headquarters to San Diego.

The company changes its name to ACADIA Pharmaceuticals Inc. and shifts its strategic focus to discovering and developing its own portfolio of product candidates. ACADIA’s headquarters is moved from Winooski, Vermont, to the biotech hub of San Diego and the company simultaneously establishes medicinal chemistry operations in Copenhagen, Denmark. Funding to support the growing operations comes from a consortium of Danish investors. The company is named after ACADIA National Park based on its historic ties to New England and the limitless power and beauty that the park inspires.

ACADIA establishes its first of several drug discovery and development collaborations with Allergan.

1993

Receptor Technologies is founded by Mark Brann, Ph.D., a professor at the University of Vermont.

Receptor Technologies is founded by Mark Brann, Ph.D., a professor at the University of Vermont. The company initially works with major pharmaceutical companies to perform high throughput screening based on its proprietary functional genomics platform, R-SAT.